Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Nov;26(11):956-964.
doi: 10.1002/onco.13848. Epub 2021 Jun 29.

Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options

Katherine Emilie Rhoades Smith  1 , Jacqueline Theresa Brown  1   2 , Limeng Wan  3 , Yuan Liu  3 , Greta Russler  2 , Lauren Yantorni  2 , Sarah Caulfield  2 , Jennifer Lafollette  4 , Melvin Moore  1   2   4 , Omer Kucuk  1   2   4 , Bradley Carthon  1   2   4 , Bassel Nazha  1   2   4 , Mehmet Asim Bilen  1   2   4
Affiliations
Multicenter Study

Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options

Katherine Emilie Rhoades Smith et al. Oncologist. 2021 Nov.

Abstract

Background: Docetaxel (DOC) and abiraterone (ABI) in the upfront setting have separately improved clinical outcomes for metastatic hormone-sensitive prostate cancer (mHSPC), but there are no studies comparing drug efficacies or the influence of racial disparities.

Materials and methods: We performed a retrospective multicenter review from Winship Cancer Institute at Emory University and Georgia Cancer Center for Excellence at Grady Memorial Hospital (2014-2020) for patients with mHSPC treated with either upfront DOC or ABI. Outcomes evaluated were overall survival (OS), progression-free survival (PFS), and prostate-specific antigen complete response (PSA CR).

Results: A total of 168 patients were included, consisting of 92 (54.8%) Black patients and 76 (45.2%) non-Black patients (69 White and 7 Asian or Hispanic). Ninety-four (56%) received DOC and 74 (44%) received ABI. Median follow-up time was 22.8 months with data last reviewed June 2020. For OS, there was no significant difference between ABI versus DOC and Black versus non-Black patients. For PFS, DOC was associated with hazard ratio (HR) 1.7 compared with ABI for all patients based on univariate association and HR 2.27 compared with ABI for Black patients on multivariable analysis. For PSA CR, Black patients were less likely to have a CR (odds ratio [OR] = 0.27).

Conclusion: ABI and DOC have similar OS with a trend toward better PFS for ABI in a cohort composed of 54% Black patients. Racial disparities were observed as prolonged PFS for Black patients treated with ABI, more so compared with all patients, and less PSA CR for Black patients. A prospective trial comparing available upfront therapies in a diverse racial population is needed to help guide clinical decision-making in the era of novel treatment options.

Implications for practice: Overall survival is similar for abiraterone and docetaxel when used as upfront therapy in metastatic hormone-sensitive prostate cancer in a cohort composed of 54% Black patients. There is a trend towards improved progression-free survival for abiraterone in all patients and Black patients. Non-Black patients were more likely to achieve prostate-specific antigen (PSA) complete response regardless of upfront therapy.

Keywords: Abiraterone; Castration-sensitive prostate cancer; Docetaxel; Racial disparities; Upfront therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1
Figure 1
Kaplan‐Meier (KM) plots for OS for patients with metastatic hormone‐sensitive prostate cancer. KM curves were generated using OS both for the entire cohort and by age group. (A): KM plot including all patients in the cohort. The ABI group has OS of 32.2 months and the DOC group has OS of 47.5 months. There was no difference in OS. (B): KM plot for Black patients only showing no difference in OS between Black patients who received ABI and DOC. (C): KM plot for non‐Black patients only also showing no difference in OS based on upfront therapy. Abbreviations: ABI, abiraterone; DOC, docetaxel; OS, median overall survival; N/A, not applicable; OS, overall survival.
Figure 2
Figure 2
Kaplan‐Meier (KM) plots for PFS for patients with metastatic hormone‐sensitive prostate cancer. KM curves were generated using PFS both for the entire cohort and by age group. (A): KM plot including all patients in the cohort showing improved PFS for those treated with ABI (p = .0272). (B): KM plot for Black patients only showing improved PFS for Black patients treated with ABI (p = .0043). (C): KM plot for non‐Black patients only showing no difference in PFS based on upfront therapies (p = .7765).Abbreviations: ABI, abiraterone; DOC, docetaxel; PFS, progression‐free survival.
See this image and copyright information in PMC

References

    1. National Cancer Institute . Cancer Stat Facts: Common Cancer Sites. Available at https://seer.cancer.gov/statfacts/html/common.html. Accessed July 6, 2020.
    1. Dalela D, Sun M, Diaz M et al. Contemporary trends in the incidence of metastatic prostate cancer among US men: Results from nationwide analyses. Eur Urol Focus 2019;5:77–90. - PubMed
    1. Kelly SP, Anderson WF, Rosenberg PS et al. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 2018;4:121–127. - PMC - PubMed
    1. Weiner AB, Matulewicz RS, Eggener SE et al. Increasing incidence of metastatic prostate cancer in the United States (2004‐2013). Prostate Cancer Prostatic Dis 2016;19:395–397. - PubMed
    1. Hahn AW, Higano CS, Taplin M‐E et al. Metastatic castration sensitive prostate cancer: Optimizing patient selection and treatment. Am Soc Clin Oncol Educ Book 2018;38:363–371. - PubMed

Publication types